Literature DB >> 6306039

Genotyping steroid 21-hydroxylase deficiency: hormonal reference data.

M I New, F Lorenzen, A J Lerner, B Kohn, S E Oberfield, M S Pollack, B Dupont, E Stoner, D J Levy, S Pang, L S Levine.   

Abstract

Hormonal reference data, in the form of nomograms relating baseline and stimulated levels of adrenal hormones, provide a means of genotyping steroid 21-hydroxylase (21-OH) deficiency in congenital adrenal hyperplasia. Data from both 360- and 60-min ACTH stimulation tests are given. The serum hormone concentrations that have proven most useful in classifying 21-OH deficiency are 17-hydroxyprogesterone and delta 4-androstenedione. These nomograms clearly distinguish the patient with classical 21-OH deficiency from those with the milder symptomatic and asymptomatic nonclassical forms of 21-OH deficiency (previously referred to as late onset and cryptic forms) as well as heterozygotes for all of the forms and those subjects predicted by HLA genotyping to be unaffected. The nomograms also can identify individuals heterozygous for 21-OH deficiency in the general population who have a characteristic heterozygote response. These nomograms provide a powerful tool by which to assign the 21-OH deficiency genotype. Patients whose hormonal values fall on the regression line within a defined group are assigned to that group. In view of the strong correlation between the 60- and 360-min ACTH stimulation tests, the less cumbersome and shorter 60-min test can be used with the same confidence as the longer test.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6306039     DOI: 10.1210/jcem-57-2-320

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  79 in total

1.  Newborn screening.

Authors:  James J Pitt
Journal:  Clin Biochem Rev       Date:  2010-05

2.  Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  P W Speiser; J Dupont; D Zhu; J Serrat; M Buegeleisen; M T Tusie-Luna; M Lesser; M I New; P C White
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

3.  Identification of nonclassical 21-hydroxylase deficiency in girls with precocious pubarche.

Authors:  M V Leite; B B Mendonça; I J Arnhold; V Estefan; C Nunes; W Nicolau; W Bloise
Journal:  J Endocrinol Invest       Date:  1991-01       Impact factor: 4.256

Review 4.  Congenital adrenal hyperplasia: an update in children.

Authors:  Christine M Trapp; Phyllis W Speiser; Sharon E Oberfield
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2011-06       Impact factor: 3.243

Review 5.  Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies.

Authors:  Manmohan K Kamboj; Andrea E Bonny
Journal:  Transl Pediatr       Date:  2017-10

6.  The clinical and biochemical spectrum of congenital adrenal hyperplasia secondary to 21-hydroxylase deficiency.

Authors:  Tony Huynh; Ivan McGown; David Cowley; Ohn Nyunt; Gary M Leong; Mark Harris; Andrew M Cotterill
Journal:  Clin Biochem Rev       Date:  2009-05

Review 7.  The next 150 years of congenital adrenal hyperplasia.

Authors:  Adina F Turcu; Richard J Auchus
Journal:  J Steroid Biochem Mol Biol       Date:  2015-06-03       Impact factor: 4.292

8.  Detection of late onset steroid 21-hydroxylase deficiency by capillary gas chromatographic profiling of urinary steroids in children and adolescents.

Authors:  J Homoki; J Solyom; W M Teller
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

9.  Premature pubarche as an indicator of how body weight influences the onset of adrenarche.

Authors:  Marie-Laure Charkaluk; Christine Trivin; Raja Brauner
Journal:  Eur J Pediatr       Date:  2003-12-19       Impact factor: 3.183

10.  Insulin and GH secretion in adolescent girls with irregular cycles: polycystic vs multifollicular ovaries.

Authors:  P Villa; A Rossodivita; A M Fulghesu; F Cucinelli; A Barini; R Apa; C Belosi; A Lanzone
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.